NCT07218315

Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is to evaluate the effectiveness of nsPFA in treating papillary thyroid microcarcinoma. T

Detailed description

Primary Objective: To evaluate the efficacy of ultrasound-guided nsPFA™ in the treatment of patients with T1N0M0 PTC as measured by the thyroid nodule volume changes including volume reduction rate (VRR), technique efficacy (TE) and nodule regrowth (NR) during post procedure follow-up. Secondary Objectives: To assess the clinical safety and complications of the CellFX Percutaneous Electrode (PE) System To evaluate the ultrasound features of thyroid nodules over time following ultrasound-guided nsPFA. To determine the health-related quality of life changes over time induced by ultrasound-guided nsPFA.

Conditions

• Thyroid Carcinoma

Interventions

Type	Name	Description
DEVICE	CellFX nsPFA Percutaneous Electrode System	Patients will undergo thyroid ablation with the CellFX nsPFA system, an outpatient procedure under local anesthesia, or intravenous sedation.

Timeline

• Start date: 2026-02-11
• Primary completion: 2029-01-31
• Completion: 2031-01-31
• First posted: 2025-10-20
• Last updated: 2026-04-02

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated device study